Seeking advice on alcohol rehabilitation?

You can receive independent, expert advice on alcohol rehabilitation and rehab centres by telephoning DryOutNow.com on 0845 370 0203.

The most important consideration in choosing a rehab centre is to match the individual to the rehab centre that is most likely to lead to a successful outcome.

DryOutNow.com can provide an assessment of all your needs and a recommendation regarding the most effective rehab placement for you, given your particular circumstances. We can provide fast, immediate access to alcohol treatment.

Rehab News: Extended treatment with combination medication for opioid addicted youths shows benefit

Adolescents addicted to opioids who received continuing treatment with the combination medication buprenorphine-naloxone had lower rates of testing positive or reporting use of opioids compared to youths who went through a short-term detoxification program using the same medication, according to a study in the November 5 issue of JAMA.

Recent data suggest that abuse of opioids, including heroin and prescription pain-relief drugs, is increasing among adolescents, according to background information in the article. "The usual treatment for opioid-addicted youth is short-term detoxification and individual or group therapy in residential or outpatient settings over weeks or months. Clinicians report that relapse is high, yet many programs remain strongly committed to this approach and, except for treating withdrawal, do not use agonist [a drug that mimics the action of a naturally occurring substance] medication," the authors write.

George Woody, M.D., of the University of Pennsylvania, Philadelphia, and colleagues conducted a study comparing outcomes of treating opioid addiction among adolescents with extended treatment using buprenorphine-naloxone vs. short-term detoxification. Buprenorphine is an oral medication that acts by relieving the symptoms of opiate withdrawal. Naloxone is a drug that prevents or reverses the effects of opioids if it is injected. The study included 152 patients, age 15 to 21 years. Patients in the 12-week buprenorphine-naloxone group were prescribed up to 24 mg. per day for 9 weeks and then tapered to week 12; patients in the detox group were prescribed up to 14 mg. per day and then tapered to day 14.

All were offered weekly individual and group counselling.

The researchers found that overall, patients in the detox group had higher proportions of opioid-positive urine test results at weeks 4 and 8 but not at week 12. At week 4, 61 percent of detox patients had positive results vs. 26 percent of the 12-week buprenorphine-naloxone patients. At week 8, 54 percent of detox patients had positive results vs. 23 percent of 12-week buprenorphine-naloxone patients. At week 12, 51 percent of detox patients had positive results vs. 43 percent of buprenorphine-naloxone patients, who by that time had been tapered off their medication.

By week 12, 20.5 percent of detox patients remained in treatment vs. 70 percent of 12-week buprenorphine-naloxone patients. During weeks 1 through 12, patients in the 12-week buprenorphine-naloxone group reported less use of opioids, cocaine and marijuana, less injecting, and less need for additional addiction treatment. High levels of opioid use occurred in both groups at follow-up.

"Taken together, these data show that stopping buprenorphine-naloxone had comparably negative effects in both groups, with effects occurring earlier and with somewhat greater severity in patients in the detox group," the authors write.

"Because much opioid addiction treatment has shifted from inpatient to outpatient where buprenorphine-naloxone can be administered, having it available in primary care, family practice, and adolescent programs has the potential to expand the treatment options currently available to opioid-addicted youth and significantly improve outcomes. Other effective medications, or longer and more intensive psychosocial treatments, may have similarly positive results. Studies are needed to explore these possibilities and to assess the efficacy and safety of longer-term treatment with buprenorphine for young individuals with opioid dependence."

Reference

Woody et al. Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth: A Randomized Trial.' JAMA, 2008; 300 (17): 2003-2011

DryOutNow.com provides highly practical help for people with alcohol problems, their friends and relatives. DryOutNow.com also provides free resources for healthcare professionals such as medical information and alcohol treatment guidelines.

Other Alcohol Rehab Related Articles

• Identifying why an individual turned to alcohol in the first place
• Detox could change individuals lives
• Reducing drinking may be easier than abstinence initially
• Detox from alcohol at home
• Social support can aid treatment outcome
• Choosing an alcohol clinic can depend on funding
• Accessing immediate treatment is not always possible via NHS.
• Are we ignoring Britains older drinker problem
• Get a a “time out” from life’s daily stresses
• Women Less Likely to Receive Alcohol Treatment
• Alcohol Detox Research Update 2
• Alcohol Detox Research Update
• Technology improves treatment options for drug users
• Socially stable individuals delay seeking help for alcohol problems
• Alkermes initiates clinical trial for ALKS 33, a novel oral molecule with potential benefits in addi
• Programme to deter youth alcohol use also reduces conduct problems
• Potential new drug for cocaine addiction and overdose, Journal of the American Chemical Society
• Are you a binge drinker, BMA Scotland calls for compulsory labelling of alcoholic drinks
• Top researchers to explore stress and anxiety, trauma, poverty and addiction seminar
• Avigen initiates opioid withdrawal trial